These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of additional Bräuer A; Rahbar K; Konnert J; Bögemann M; Stegger L Nuklearmedizin; 2017 Feb; 56(1):14-22. PubMed ID: 28074210 [TBL] [Abstract][Full Text] [Related]
4. 68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer. Ahmadzadehfar H; Schlenkhoff CD; Rogenhofer S; Yordanova A; Essler M Clin Nucl Med; 2016 Sep; 41(9):695-6. PubMed ID: 27405025 [TBL] [Abstract][Full Text] [Related]
5. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731 [TBL] [Abstract][Full Text] [Related]
6. Detection Efficacy of Hybrid Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912 [TBL] [Abstract][Full Text] [Related]
7. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844 [TBL] [Abstract][Full Text] [Related]
9. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639 [TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035 [TBL] [Abstract][Full Text] [Related]
12. Value of post-therapy Tuncel M; Telli T Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750 [TBL] [Abstract][Full Text] [Related]
13. Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013 [TBL] [Abstract][Full Text] [Related]
15. Clinical performance of Kranzbühler B; Nagel H; Becker AS; Müller J; Huellner M; Stolzmann P; Muehlematter U; Guckenberger M; Kaufmann PA; Eberli D; Burger IA Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):20-30. PubMed ID: 29032394 [TBL] [Abstract][Full Text] [Related]
16. Detection Rate and Localization of Prostate Cancer Recurrence Using Kranzbühler B; Müller J; Becker AS; Garcia Schüler HI; Muehlematter U; Fankhauser CD; Kedzia S; Guckenberger M; Kaufmann PA; Eberli D; Burger IA J Nucl Med; 2020 Feb; 61(2):194-201. PubMed ID: 31375566 [TBL] [Abstract][Full Text] [Related]
17. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952 [TBL] [Abstract][Full Text] [Related]
18. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy. Henkenberens C; von Klot CA; Ross TL; Bengel FM; Wester HJ; Merseburger AS; Vogel-Claussen J; Christiansen H; Derlin T Strahlenther Onkol; 2016 Jul; 192(7):431-9. PubMed ID: 27272755 [TBL] [Abstract][Full Text] [Related]
19. Comparison of [ Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246 [TBL] [Abstract][Full Text] [Related]
20. Correlation between molecular tumor volume evaluated with Medina-Ornelas Sevastián S; García-Pérez Francisco O; Hernández-Pedro Norma Y; Arellano-Zarate Angélica E; Abúndiz-López Blanca L Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):223-228. PubMed ID: 29454548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]